United States Patent
US Patent 7063849: Use of HIV-1 gp120 and gp160 proteins modified in…
US 7063849 · granted 2006-06-20
Abstract
Use of HIV-1 gp120 and gp160 proteins which have been modified in the V3 loop for preparing vaccine compositions and formulations containing them which induce a systemic and mucosal immunity.Use of a recombinant HIV-1 Env protein, in which the V3 loop is partially or completely deleted, for preparing a vaccine composition which is capable of inducing an immunity which is at the same time humoral, cellular and mucosal with respect to HIV-1.The vaccine composition comprises:a recombinant Env protein as defined above,optionally at least one compound selected from the group consisting of: (1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminium hydroxide or calcium phosphate, and muramylpeptide derivatives and (2) liposomes andoptionally at least one pharmaceutically acceptable vehicle.
| Patent Number | 7063849 |
|---|---|
| Title | Use of HIV-1 gp120 and gp160 proteins modified in the v3 loop for the preparation of vaccine compositions and formulations containing the same |
| Filed | 2000-08-04 |
| Granted | 2006-06-20 |
| Inventor(s) | Lavallee; Claude, Thibodeau; Lise |
| Assignee | Fondation Mondiale Recherche et Prevention Sida |
| CPC Classification | A61K 39/21 |
| Number of Claims | 20 |
Abstract
Use of HIV-1 gp120 and gp160 proteins which have been modified in the V3 loop for preparing vaccine compositions and formulations containing them which induce a systemic and mucosal immunity.Use of a recombinant HIV-1 Env protein, in which the V3 loop is partially or completely deleted, for preparing a vaccine composition which is capable of inducing an immunity which is at the same time humoral, cellular and mucosal with respect to HIV-1.The vaccine composition comprises:a recombinant Env protein as defined above,optionally at least one compound selected from the group consisting of: (1) the vaccination adjuvants selected from the group consisting of derivatives comprising divalent or trivalent ions: aluminium hydroxide or calcium phosphate, and muramylpeptide derivatives and (2) liposomes andoptionally at least one pharmaceutically acceptable vehicle.
Claim 1
An immunogenic composition formulated for local administration directly to a mucous membrane comprising a recombinant HIV-1 envelope protein comprising a mutated V3loop, wherein the mutated V3 loop comprises the GPGRAF (SEQ ID NO: 1) hexamer sequence flanked by the two basal cysteines but lacks all or a portion of the rest of the V3 loop, said recombinant HIV-1 envelope protein being anchored onto preformedliposomes.
Claims
20 totalAn immunogenic composition formulated for local administration directly to a mucous membrane comprising a recombinant HIV-1 envelope protein comprising a mutated V3loop, wherein the mutated V3 loop comprises the GPGRAF (SEQ ID NO: 1) hexamer sequence flanked by the two basal cysteines but lacks all or a portion of the rest of the V3 loop, said recombinant HIV-1 envelope protein being anchored onto preformedliposomes.